Biotech Companies Respond to Coronavirus (COVID-19)

Biopharmaceutical Innovators Lead the Charge in Fight Against Coronavirus

As a total healthcare company, Fujifilm is committed to supporting global efforts to counter the COVID-19 pandemic.

Learn more

Diagnostics

Genentech has initiated a Phase III clinical trial of Actemra in hospitalized patients with severe COVID-19 pneumonia.

Learn more

Therapeutics

Generex has been working to develop a peptide vaccine against the new coronavirus SARS-CoV-2.

Learn more

Vaccines

GeoVax is using its GV-MVA-VLP vaccine platform to develop a vaccine for COVID-19.

Learn more

Vaccines

Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir.

Learn more

Therapeutics

Grifols has shared technology in convalescent plasma and is working on diagnostic and screening tests.

Learn more

Diagnostics

GSK is supplying vaccine adjuvant technology to scientists and organizations working on a vaccine.

Learn more

Vaccines

Humanigen is evaluating lenzilumab for the prevention and treatment of cytokine storm arising from COVID-19.

Learn more

Therapeutics

iBio has developed SARS-CoV-2 Virus-Like Particle (“VLP”) using its FastPharming System™.

Learn more

Vaccines

IMV Inc. is developing a vaccine candidate against COVID-19 based on its DPX delivery platform.

Learn more

Vaccines

Incyte has initiated RUXCOVID, a Phase 3 clinical trial, and an Expanded Access Program with ruxolitinib.

Learn more

Therapeutics

InflaRX is investigating the safety and efficacy of IFX-1, the company´s monoclonal anti-C5a antibody.

Learn more

Therapeutics

Biotech Companies Are Responding Faster Than Ever to Emerging Health Threats

Biopharmaceutical Innovators Are Leading The Charge In Fight Against Coronavirus

Here's a snapshot of how our industry is responding to the coronavirus.

Download PDF

BIO Members Are Working Around The Clock To Find Solutions To Combat Coronavirus

Learn about how the biopharmaceutical industry is responding to the coronavirus.

Download PDF

COVID-19 Vaccine Supply Chain: How We Will Vaccinate the Globe

To ensure people get safe and effective vaccines as quickly as possible, biotechnology companies have leveraged global partnerships and
innovative collaborations to reach patients all around the world.

Download PDF

BIO/ BioCentury Survey: COVID-19 Impact on Clinical Trials

A joint survey from BIO and BioCentury finds companies are seeking guidance and regulatory flexibility, while at the same time moving to remote monitoring and telemedicine for ongoing trials.

Download

Biotech Leaders Hit the Airwaves to Talk About Industry’s Efforts to Eradicate Covid-19

As the novel coronavirus continues to spread, scientists and researchers are working around the clock to identify diagnostics, therapeutics and vaccines to help protect individuals and communities across the globe.

Learn More

BIO's Virtual Summit Recap

On March 24-25, 2020, BIO virtually convened more than 500 leaders from across industry, government, academia, and NGOs to assess the state of the pandemic and accelerate medical countermeasure solutions for COVID-19.

Download

Vaccine Development, Manufacturing and Distribution During a Pandemic

Learn about how a COVID-19 vaccine will be procured and distributed during the public health emergency.

Download PDF

BIO Coronavirus Events

BIO virtually brought together 45 biotech innovators, government agencies, and leading academics to share information about their work to fight the coronavirus.

In addition, view the BIO Europe Spring Combating Coronavirus virtual session.

Learn More

Hear from BIO's Coronavirus Lead

George Scangos, Ph.D., President and Chief Executive Officer of Vir Biotechnology, has been selected to lead the Biotechnology Innovation Organization's response to Coronavirus (COVID-19). Dr. Scangos explains what this role means and why collaboration across the private, public and NGO sectors is vital in combating Coronavirus.

Watch the Video

The Coronavirus Is No Match for Science, but We Must Finish the Job

Jim Greenwood in Morning Consult: The science is galloping forward, and collaboration between the public and private sectors is vital to combat the coronavirus. BIO is taking the lead to connect innovators with partners inside the federal government.

Learn More